ESMO 2023

Exploring Sintilimab's R&D successes and its clinical results at the 2023 ESMO_ASIA

25 December 2023
4 min read

The combination of ICIs and anti-angiogenic therapy has a synergistic anti-tumor effect and can improve the prognosis of advanced NSCLC patients. On 2 Dec 2023, the latest clinical trial about Sintilimab in combination with anlotinib in 2023 ESMO_ASIA further demonstrated the therapeutic benefits.

Sintilimab's R&D Progress

Sintilimab is a monoclonal antibody drug that targets PD-1, a protein involved in regulating the immune system. The drug has shown promise in treating a wide range of therapeutic areas, including neoplasms, digestive system disorders, skin and musculoskeletal diseases, urogenital diseases, immune system diseases, hemic and lymphatic diseases, and respiratory diseases.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the Patsnap Synapse, Sintilimab has been developed by Innovent Biologics (Suzhou) Co. Ltd. and has received approvals globally. And the clinical trial distributions for Sintilimab are primarily in the United States, China and United Kingdom. The key indication is Hepatocellular Carcinoma.

表格, 日历

描述已自动生成

Detailed Clinical Result of Sintilimab

This single group assignment, open-labeled clinical trial (NCT04691388) was designed to evaluate the efficacy and safety of sintilimab in combination with anlotinib in NSCLC disease progressed after first-line treatment with anti-PD-1 antibody.

图形用户界面, 文本, 应用程序, Teams

描述已自动生成

In this study, NSCLC patients with disease progression after first-line treatment with anti-PD-1 antibody were enrolled. Sintilimab (200 mg, day 1) in combination with anlotinib (12mg, day 1 to 14) were given every 3 weeks. Primary end point is objective response rate (ORR) evaluated via RECIST 1.1. Key secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and safety (CTCAE 5.0).

图形用户界面, 应用程序

描述已自动生成

The result showed that from 3/2021 to 6/2023, 17 patients were enrolled. The median age was 63 years old (range 45-73) and 100% (17/17) was male. In 14 patients with efficacy data, 14.3% (2/14) achieved partial response (PR) and 71.4% (10/14) achieved stable disease (SD). ORR and DCR were 14.3% (and 85.7%, respectively. Until the last follow-up, the median PFS was 6.0 months95% CI, range 4.2-7.7 months, 6-month PFS rate was 56.4%. The median OS was 17.9 months95% CI, range 5.6-NA months, 12-month OS rate was 64.6%. Grade 3/4 treatment-related adverse events (TRAEs) included: hand and foot skin reaction (5.9%, 1/17), increased alanine aminotransferase (5.9%, 1/17), hypertension (11.8%, 2/17), hypertriglyceridemia (5.9%, 1/17) and neutropenia (5.9%, 1/17). No treatment-related deaths occurred.

It can be concluded that the combination of sintilimab and anlotinib could be an effective and safe option for NSCLC.

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

图形用户界面, 应用程序, Teams

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

Click on the image below to embark on a brand new journey of drug discovery!

What are TYK2 inhibitors and how do you quickly get the latest development progress?
What are TYK2 inhibitors and how do you quickly get the latest development progress?
25 December 2023
Selecting TYK2 inhibitors can reduce the inhibition of other immune-related pathways in the body, reduce the risk of infection, and be safer in clinical practice.
Read →
Travere Therapeutics starts key Phase 3 trial of Pegtibatinase for Classical Homocystinuria (HCU) management
Latest Hotspot
3 min read
Travere Therapeutics starts key Phase 3 trial of Pegtibatinase for Classical Homocystinuria (HCU) management
25 December 2023
Travere Therapeutics has begun a critical Phase 3 study of Pegtibatinase in the management of Classical Homocystinuria (HCU).
Read →
Does the divided dose of yellow fever vaccine present a greater risk of adverse reactions?
Knowledge Base
2 min read
Does the divided dose of yellow fever vaccine present a greater risk of adverse reactions?
25 December 2023
The fractional dose comes from the same full dose vaccine. It has been given to millions of people to prevent yellow fever in the past.
Read →
Zenocutuzumab: A Quick Look at Its R&D Progress and Clinical Results from the 2023 ESMO_ASIA
ESMO 2023
4 min read
Zenocutuzumab: A Quick Look at Its R&D Progress and Clinical Results from the 2023 ESMO_ASIA
25 December 2023
Zenocutuzumab (MCLA-128; Zeno) is a bispecific antibody that overcomes HER3-mediated NRG1 signaling in NRG1+ cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.